Giuseppe Inesi1, Rajendra Pilankatta2, Francesco Tadini-Buoninsegni3. 1. *California Pacific Medical Center Research Institute, San Francisco, CA 94920, U.S.A. 2. †Department of Biochemistry and Molecular Biology, Central University of Kerala, Padennakkad (P.O), Nileshwar, Kasaragod-671 314, Kerala, India. 3. ‡Department of Chemistry "Ugo Schiff", University of Florence, 50019 Sesto Fiorentino, Italy.
Abstract
Copper ATPases, in analogy with other members of the P-ATPase superfamily, contain a catalytic headpiece including an aspartate residue reacting with ATP to form a phosphoenzyme intermediate, and transmembrane helices containing cation-binding sites [TMBS (transmembrane metal-binding sites)] for catalytic activation and cation translocation. Following phosphoenzyme formation by utilization of ATP, bound copper undergoes displacement from the TMBS to the lumenal membrane surface, with no H+ exchange. Although PII-type ATPases sustain active transport of alkali/alkali-earth ions (i.e. Na+, Ca2+) against electrochemical gradients across defined membranes, PIB-type ATPases transfer transition metal ions (i.e. Cu+) from delivery to acceptor proteins and, prominently in mammalian cells, undergo trafficking from/to various membrane compartments. A specific component of copper ATPases is the NMBD (N-terminal metal-binding domain), containing up to six copper-binding sites in mammalian (ATP7A and ATP7B) enzymes. Copper occupancy of NMBD sites and interaction with the ATPase headpiece are required for catalytic activation. Furthermore, in the presence of copper, the NMBD allows interaction with protein kinase D, yielding phosphorylation of serine residues, ATP7B trafficking and protection from proteasome degradation. A specific feature of ATP7A is glycosylation and stabilization on plasma membranes. Cisplatin, a platinum-containing anti-cancer drug, binds to copper sites of ATP7A and ATP7B, and undergoes vectorial displacement in analogy with copper.
Copper ATPases, in analogy with other members of the P-ATPase superfamily, contain a catalytic headpiece including an aspartate residue reacting with ATP to form a phosphoenzyme intermediate, and transmembrane helices containing cation-binding sites [TMBS (transmembrane metal-binding sites)] for catalytic activation and cation translocation. Following phosphoenzyme formation by utilization of ATP, bound copper undergoes displacement from the TMBS to the lumenal membrane surface, with no H+ exchange. Although PII-type ATPases sustain active transport of alkali/alkali-earth ions (i.e. Na+, Ca2+) against electrochemical gradients across defined membranes, PIB-type ATPases transfer transition metal ions (i.e. Cu+) from delivery to acceptor proteins and, prominently in mammalian cells, undergo trafficking from/to various membrane compartments. A specific component of copper ATPases is the NMBD (N-terminal metal-binding domain), containing up to six copper-binding sites in mammalian (ATP7A and ATP7B) enzymes. Copper occupancy of NMBD sites and interaction with the ATPase headpiece are required for catalytic activation. Furthermore, in the presence of copper, the NMBD allows interaction with protein kinase D, yielding phosphorylation of serine residues, ATP7B trafficking and protection from proteasome degradation. A specific feature of ATP7A is glycosylation and stabilization on plasma membranes. Cisplatin, a platinum-containing anti-cancer drug, binds to copper sites of ATP7A and ATP7B, and undergoes vectorial displacement in analogy with copper.
The superfamily of P-type ATPases comprises membrane-bound enzymes that utilize the potential energy of ATP for active transport of ions [1-4]. The P-type denomination refers to (alkali-labile and acid-stable) phosphorylation of an aspartate residue by ATP within the catalytic site. This phosphorylation reaction is an intermediate step for energy transduction and vectorial displacement of bound ions, before hydrolytic cleavage of Pi. The structure of these enzymes includes a headpiece above the membrane cytosolic surface, containing domains for ATP-binding (N domain), phosphoryl transfer (P domain) and catalytic activation (A domain). On the other hand, binding sites for specific ions [TMBS (transmembrane metal-binding sites)] reside within the membrane-bound region, with participation of residues from various transmembrane helices. Energy transduction occurs through a long-range mechanism, including sequential changes of protein conformation, allowing cation binding with high affinity on one side of the membrane, followed by vectorial displacement and release with lower affinity from the other side (Scheme 1).
Scheme 1
Schematic diagram of sequential reactions in the catalytic cycle of the Ca2+ ATPase
Following Ca2+ binding to the enzyme in state E1, ATP utilization yields a phosphorylated intermediate, whereupon utilization of phosphorylation potential yields the E2 conformation, which allows vectorial displacement and release of bound Ca2+ in exchange for H+.
Schematic diagram of sequential reactions in the catalytic cycle of the Ca2+ ATPase
Following Ca2+ binding to the enzyme in state E1, ATP utilization yields a phosphorylated intermediate, whereupon utilization of phosphorylation potential yields the E2 conformation, which allows vectorial displacement and release of bound Ca2+ in exchange for H+.Detailed characterization of P-type ATPases involved in active transport of Na+ or Ca2+ was favoured by their natural abundance in native membranes, permitting biochemical and crystallographic studies [5-11]. In addition, the concentrations of alkali and alkali-earth ions within membrane-delimited compartments are fairly high (0.1 μM-mM), permitting estimates of free ion concentrations and transmembrane electrochemical gradients, as well as determinations of bound ion stoichiometry by the use of radioactive tracers. On the other hand, characterization of transition metal ion P-ATPases has been more difficult due to low quantities of these enzymes in native membranes, and extremely low concentrations of transition metal ions (e.g. copper) within intra- and extra-cellular fluids. Furthermore, the physiology of cytosolic transition metal homoeostasis is rather complex, as it involves transporters such as chaperone proteins, delivering ions to P-ATPases on one side of the membrane, and receiving them from the other side. Important and general information on P-type copper ATPases and on related cellular mechanisms has been given previously [12-18]. The present review is focused on the biochemical properties of copper ATPases, reporting available information on catalytic events related to cation translocation, reactions favouring cellular trafficking of ATPases, and roles of various domains within the ATPase protein.
BACTERIAL COPPER P-TYPE ATPases
Cu+-ATPases contribute to bacterial homoeostasis through their involvement in Cu+ detoxification and cuproprotein assembly. Original and fundamental contributions to characterization of bacterial copper ATPases were obtained by the use of the thermophilic Archaeoglobus fulgidus CopA as a model protein within the subfamily of PIB-type ATPases. Functional characterization [19] of the cloned and heterologously expressed protein indicated that this CopA enzyme is active at high temperature (75°C) in the presence of Ag+ or Cu+, utilizing ATP by formation of an acid stable intermediate, and proceeding with hydrolytic activity at a maximal rate of 3.66 μmol/mg per h in the presence of Cu+. The metal concentration dependence of enzyme activation observed is in the micromolar range (Supplementary Figure S1 at http://www.biochemj.org/bj/463/bj4630167add.htm).A comparison (Figure 1) of PIB-type ATPases with the Na+/K+-ATPase α subunit (a typical PII-type ATPase) shows that the A. fulgidus CopA is an 804 amino acid protein matching the typical topological pattern of other PIB-type ATPases, with a large cytoplasmic loop containing the DKTGT sequence (as in the PII-type) and eight transmembrane segments (rather than ten as in the PII-type). Invariant residues in the transmembrane region (two cysteine residues and a tyrosine for site I, and an asparagine, a methionine and a serine for site II) contribute to two high-affinity TMBS, whose simultaneous occupancy is required for enzyme turnover [20,21]. Furthermore, the A. fulgidus CopA has an NMBD (N-terminal metal-binding domain) with a single Cu+-binding motif (CXXC) at the N-terminal, which is not present in PII-type ATPases. The NMBD increases in length, with a higher number of Cu+-binding motifs in other PIB-type ATPases, up to six in eukaryotic enzymes (Figure 1). Cryoelectron microscopy of bacterial CopA tubular crystals reveals that the NMBD interacts with the cytosolic headpiece, suggesting a Cu-dependent regulatory role for the NMBD [22].
Figure 1
Membrane topology and sequential arrangement of conserved functional domains of CPx-ATPases
Diagram of the T. maritima CopA reaction sequences indicating that the enzyme can be phosphorylated by ATP, or even by Pi in the absence of Cu+, yielding a phosphoenzyme species (Eb-P) undergoing very slow turnover
Diagram of the T. maritima CopA reaction sequences indicating that the enzyme can be phosphorylated by ATP, or even by Pi in the absence of Cu+, yielding a phosphoenzyme species (Eb-P) undergoing very slow turnover
Effect of copper on the digestion pattern of T. maritima CopA WT, ΔNMBD (NMBD entirely removed) and CXXC (double mutation of C17A and C20A in the NMBD) proteins
Effect of copper on the digestion pattern of T. maritima CopA WT, ΔNMBD (NMBD entirely removed) and CXXC (double mutation of C17A and C20A in the NMBD) proteins
If CopA with deletion of the NMBD (Figure 3: ΔNMBD) is used, the intact protein migrates as a p70 band reflecting the NMBD deletion. In the absence of copper, production of the p44 fragment (i.e. cleavage at Ser328 on the A domain–M3 loop) occurs within a time frame similar to that observed with the WT protein (compare digestion in panels a and b of Figure 3). In the presence of copper, the p70 protein is protected and the yield of p44 fragment is reduced, as observed with the WT protein. This indicates that the protective conformational effect is induced by copper binding to the TMBS, since the NMBD is absent. Therefore Cu+ can be bound by TMBS even in the absence of the NMBD segment.If the NMBD CXXC mutant is used, the same digestion pattern observed with both WT and ΔNMBD in the absence of copper is obtained. However, in this case, addition of copper does not produce any protection (Figure 3c), indicating that the copper-free NMBD (CXXC mutant) prevents the protective conformational change induced by the copper binding to the TMBS, as required for enzyme activation.The experimental evidence reported so far indicates that, following catalytic activation by concerted effects of NMBD and TMBS copper occupancy, ATP is utilized in analogy to other P-type ATPases to form [2Cu+·E1 P] where E1 P is a high-energy phosphorylated intermediate with 2Cu+ bound at the TMBS sites, expected to undergo vectorial translocation (Scheme 1). The phosphorylated moiety potential energy is then utilized for the conformational transition of [2Cu+·E1 P·P] to [2Cu+·E2-P], thereby reducing the affinity and changing the orientation of Cu+ bound to the TMBS sites. Vectorial displacement of bound Cu+ would then be followed by hydrolytic cleavage of Pi, yielding E2·Pi and final release of Pi. It is apparent that interaction of NMBD with the catalytic headpiece, and consequent A domain movements, play important roles in the sequential reactions of the ATPase cycle. This may be accomplished by facilitating Cu+ entry to the TMBS and, most importantly, by allowing proper placement of the A domain conserved catalytic sequence near the P domain phosphorylated site, thereby facilitating the hydrolytic reaction. Copper occupancy of the NMBD remains most likely throughout the cycle, whereas copper bound to the TMBS is released with each cycle.It is of interest that defective ATP utilization is produced by a histidine residue mutation (H479Q) in the bacterial T. maritima CopA (Figure 2), in analogy to that produced by the corresponding mutation in humanWilson diseasecopperATPase (ATP7B) [34].Specific and novel information on the final steps of the L. pneumophila CopA catalytic cycle was obtained following crystallization of the enzyme in the absence of copper and in the presence of BeF3−, yielding an E2-P state analogue. It was inferred from this crystal structure that the enzyme transmembrane domain positions in E2-P and E2·Pi states retains structural similarity [35]. In addition, molecular dynamics simulations show extracellular water solvated within the transmembrane domain, indicating that the transmembrane domains of the E2-P and the E2·Pi states are both open towards the extracellular side, thus suggesting a class-specific ion-release pathway originating from ion-binding residues deep within the transmembrane domain, allowing Cu+ release as shown in Scheme 2 (deeper colour).It should be pointed out that, in contrast with CopA (Scheme 3), a conformational change between E2-P and E2·Pi was clearly demonstrated for the Ca2+ ATPase [36], consisting of movements and rotation of transmembrane helices, opening and closing a switch of the lumenal Ca2+ release gate, in conjunction with H+ exchange. Therefore the crystal structures of Cu+-ATPase from L. pneumophila obtained so far, in conjunction with site-directed mutagenesis and molecular dynamics simulations, indicate a copper transport pathway across the membrane, where Cu+-ATPases couple dephosphorylation and ion extrusion differently than do the well-characterized PII-type ATPases [37]. Furthermore, although Ca2+/H+ exchange occurs in the Ca2+ ATPase (Scheme 1), no evidence of counterion binding is available for the Cu+-ATPase.
Scheme 3
Reaction scheme proposed for the L. pneumophila CopA, where the headpiece domains are shown in yellow (A), red (N), blue (P) and light blue (NMBD), and the coloured arrows indicate their movements
Note that the transmembrane domains undergo no major movements in the transition between E2-P and E2Pi. However, as explained above, conformational transitions occur upon Cu+ binding to the NMBD and TNBS, as well as upon utilization of ATP. Most importantly, the (Cu•) E1 P to (Cu•) E2-P conformational transition is related to utilization of phosphorylation potential, resulting in vectorial displacement of bound Cu+. Reprinted by permission from Macmillan Publishers Ltd: Nature Structural and Molecular Biology [35] Andersson, M., Mattle, D., Sitsel, O., Klymchuk, T., Nielsen, A. M., Møller, L. B., White, S. H., Nissen, P. and Gourdon, P. (2014) Copper-transporting P-type ATPases use a unique ion-release pathway. Nat. Struct. Mol. Biol. 21, 43–48, copyright (2014)
Reaction scheme proposed for the L. pneumophila CopA, where the headpiece domains are shown in yellow (A), red (N), blue (P) and light blue (NMBD), and the coloured arrows indicate their movements
Note that the transmembrane domains undergo no major movements in the transition between E2-P and E2Pi. However, as explained above, conformational transitions occur upon Cu+ binding to the NMBD and TNBS, as well as upon utilization of ATP. Most importantly, the (Cu•) E1 P to (Cu•) E2-P conformational transition is related to utilization of phosphorylation potential, resulting in vectorial displacement of bound Cu+. Reprinted by permission from Macmillan Publishers Ltd: Nature Structural and Molecular Biology [35] Andersson, M., Mattle, D., Sitsel, O., Klymchuk, T., Nielsen, A. M., Møller, L. B., White, S. H., Nissen, P. and Gourdon, P. (2014) Copper-transporting P-type ATPases use a unique ion-release pathway. Nat. Struct. Mol. Biol. 21, 43–48, copyright (2014)
MAMMALIAN COPPER P-TYPE ATPases
The identity and importance of human P-type copper ATPases was first noted in genetic analysis of patients affected by Menkes’ disease, demonstrating abnormalities in a gene related to P-type cation-transport ATPases [38]. This enzyme was then named ATP7A, and will be referred to as such in the present review. It was also reported that the gene responsible for Wilson's disease encodes a copper transport ATPase that has homology with the Menkes’ disease gene [39-41]. This enzyme was then named ATP7B, and will be referred to as such in the present review. Subsequent studies, reviewed by Lutsenko et al. [42] and Veldhuis et al. [43], expanded information on the structural organization and functional properties of the ATP7A and ATP7B isoforms. It is clear that the two enzymes play an essential role in cellular physiology, as they are involved in transfer of dietary copper from enterocytes into blood, export of copper from liver into bile, maintain intracellular copper below toxic levels by translocation from the cytosol across cellular membranes, and contribute to protein biosynthesis by delivering copper into the lumen of the secretory pathway where the metal ion is incorporated into copper-dependent enzymes. They also sustain specialized roles such as systemic copper absorption (ATP7A) and copper excretion (ATP7B), and maintain copper homoeostasis in various tissues such as brain, kidney, lungs, mammary gland, heart and placenta. Important properties of these enzymes are related to their trafficking [16,44] between the trans-Golgi network and exocytic vesicles located at or proximal to the apical (ATP7B) or basolateral (ATP7A) cell surface. Interaction with other proteins and involvement of signalling kinases appear to be involved in the activating function and trafficking of mammaliancopper ATPases.The structure of mammaliancopper ATPases (Figure 4), in analogy with bacterial copper ATPases [45], comprises a headpiece with the N, P and A domains and conserved catalytic motifs, and eight transmembrane segments including TM4, TM5 and TM6 that display characteristic CPX motifs for copper binding (TMBS) involved in catalytic activation and subjected to vectorial translocation. A specific feature of mammaliancopper ATPases is an NMBD comprising six (rather than one as in the bacterial enzyme) copper-binding sites [46-49]. The NMBD extension, shown to comprise flexible elements [50], is involved in interactions with partner proteins and sustains copper-induced and functionally relevant conformational effects. Although the crystal structure of the mammaliancopper ATPases is not available as yet, solution structures of specific domains have been obtained by spectroscopic methods [50-52].
Figure 4
2D folding model of the (mammalian) ATP7B sequence
Phosphoenzyme formation and vectorial displacement of bound copper
The native abundance of copper ATPases is quite low and, for this reason, biochemical experimentation has been conducted with recombinant protein obtained by heterologous expression in yeast or insect cells [48,53,54], providing evidence for phosphorylation upon addition of ATP. Characterization of the biochemical properties of mammalian P-type copper ATPases were significantly aided by high-yield heterologous expression in cultured mammalian cells following cDNA transfer with viral vectors [55]. It was found that the microsomal fraction of cell homogenates containing heterologously expressed ATP7B sustains a copper-dependent steady-state ATPase activity of 50–150 nmol of Pi/mg of protein per min at 37°C, pH 6.0. Since the expressed ATP7B accounts for approximately 20% of the total protein, it can be estimated that the specific ATPase activity would be 0.25–0.75 μmol/mg of ATP7B protein per min. This value is much lower than that observed with the Ca2+ ATPaseSERCA1 (sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 1) under optimal conditions (2–5 μmol/mg per min). The lower rate was confirmed by measurements of exponential phosphoenzyme decay (see Supplementary Figure S5) after its formation by ATP addition to enzyme pre-equilibrated with Cu+, under conditions which are not influenced by the enzyme concentration and may not be influenced by chaperones affecting copper delivery before phosphoenzyme formation. The phosphorylation experiments yield basic information on kinetic features of the ATPase, such as phosphorylated intermediate formation and decay, as their rates are influenced by specific interactions (i.e. NMBD), site-directed mutations and deletions. This biochemical information may become very useful to interpret crystallographic data when available.Another important feature permitted by the high-yield expression is the demonstration that, upon addition of ATP, enzyme phosphorylation occurs with biphasic kinetics, and steady-state hydrolytic cleavage of Pi begins in conjunction with the fast component of alkali labile phosphoenzyme production, and does not increase further as protein phosphorylation continues at a slow rate to produce alkali-resistant phosphoprotein (Supplementary Figure S3 at http://www.biochemj.org/bj/463/bj4630167add.htm). Only the first component corresponds to phosphorylation of Asp1027 (P domain) to form the phosphoenzyme catalytic intermediate which, as expected, is stable at acid pH and labile at alkaline pH. In fact, its formation is totally prevented by site-directed D1027N mutation (Supplementary Figure S4 at http://www.biochemj.org/bj/463/bj4630167add.htm). In addition, exponential decay of the acid-stable fast component of [32P]phosphoenzyme (obtained with [γ-32P]ATP) is observed following chase with non-radioactive ATP [56], and occurs with a rather slow decay rate (Supplementary Figure S5 at http://www.biochemj.org/bj/463/bj4630167add.htm), consistent with the steady-state ATPase velocity, and corresponds to the rate constant of phosphoezyme intermediate hydrolytic cleavage in the forward direction of the catalytic cycle [56].It has become possible, using a technique based on absorption of membrane-bound ATPase on to a hybrid alkane thiol/phospholipids bilayer anchored to a gold electrode (solid supported membrane), to detect charge movements due to ion displacement within the ATPase protein upon addition of ATP [57]. The electrical current recorded by this method is a measure of the rate of change of the transmembrane potential and is not sensitive to steady-state phenomena. Therefore only the charge movement within the first enzyme cycle is recorded. Using microsomes of COS1 cells expressing ATP7A or ATP7B with high yield, it was then demonstrated with pre-steady-state current measurements that within a single catalytic cycle following addition of ATP, TMBS-bound copper undergoes electrogenic movement within the ATP7B protein, consistent with vectorial displacement towards the lumenal membrane surface [58]. This charge movement is totally prevented by mutations of either the TMBS site or the sixth NMBDcopper-binding site, demonstrating the specificity of this phenomenon with regard to the enzyme cycle. Comparison of the time constants for cation displacement in the copper and in the calcium transport ATPases [58] is consistent with the slower copperATPase phosphoenzyme formation. Interestingly, although charge transfer is reduced by alkaline pH in the Ca2+ ATPase (Supplementary Figure S6 at http://www.biochemj.org/bj/463/bj4630167add.htm) since Ca2+/H+ exchange is required for vectorial displacement of bound Ca2+ [59], no effect of pH is observed with the copperATPase (Supplementary Figure S6) indicating that copper displacement does not require H+ exchange [56]. It is clear that the initial formation of alkali-labile phosphoenzyme upon addition of ATP is soon followed by vectorial displacement of bound copper from the TMBS to the lumenal membrane surface.
Phosphorylation of serine residues, the NMBD segment and ATP7B trafficking
The slower component of ATP7B phosphorylation by ATP occurs with the same pattern ex vivo (cell cultures) and in vitro (microsomes). Using microsomes of COS1 cells expressing ATP7A or ATP7B with high yield, it was then possible to demonstrate [55] by proteolysis and MS that slow phosphorylation involves Ser478 and Ser481 (NMBD), Ser1121 (N-terminal domain) and Ser1453 (C-terminus), as shown in Figure 4. Most importantly, although formation of enzyme intermediate is due to direct phosphorylation of Asp1027 by ATP, phosphorylation of serine residues is catalysed by PKD (protein kinase D), and is abolished by specific PKD inhibition with CID755673 [60]. The same pattern of phosphorylation is observed with ATP7B expressed in COS1 cells or hepatocytes. Under comparative conditions, it is found that the slow alkali-resistant phosphorylation does not occur at all with the Ca2+ ATPase (Supplementary Figure S4).Experiments conducted following site-directed mutations demonstrate that aspartate residue (Asp1027) phosphorylation is interfered with by either mutations involving the TMBS or the sixth NMBDcopper site (Supplementary Figure S7 at http://www.biochemj.org/bj/463/bj4630167add.htm), whereas inhibition of serine phosphorylation is only observed following mutation of the sixth NMBDcopper site. It is of interest that, following deletion of the terminal NMBD segment including five copper sites (Δ5 protein), aspartate phosphorylation (but not serine phosphorylation) still occurs [56] as long as copper is bound to the TMBS (Supplementary Figure S8 at http://www.biochemj.org/bj/463/bj4630167add.htm). Such an intermediate undergoes the expected catalytic decay. This suggests that, in the absence of copper, the NMBD interacts with the enzyme headpiece, interfering with formation of the phos-phorylated enzyme intermediate (i.e. aspartate) even in the presence of copper on the TMBS. This interference can then be removed by copper binding to the NMBD, consistent with previous observations by Huster and Lutsenko [49].Even more intriguing results are obtained when ATP7B and Δ5 (deletion of the first five NMBD sites) proteins are tested for their ability to undergo reverse phosphorylation by Pi, a reaction obtained with the Ca2+ ATPase as long as Ca2+ is removed to destabilize the protein. It was then found that WT ATP7B is unable to react with Pi even if copper is removed. On the other hand, the Δ5 protein reacts with Pi [56]. These experiments indicate that in the WT enzyme and in the absence of copper, the NMBD interacts with the enzyme headpiece, interfering with the reverse formation of phosphoenzyme intermediate (i.e. aspartate) by utilization of Pi.The PKD involved in slow and alkaline-resistant phosphorylation is a serine/threonine kinase associated with the trans-Golgi network, regulating recruitment of transport carriers destined to the cell surface. In fact, studies on cultured cells sustaining heterologous expression show that nascent WT ATP7B transits to the Golgi complex [60] where it undergoes serine phosphorylation by PKD. It is of interest that serine phosphorylation protects nascent ATP7B from proteasome-mediated degradation. As a final step, phosphorylated ATP7B is transferred from the Golgi complex to cytosolic trafficking vesicles (Figure 5). This is observed even following Asp1027 mutation. On the other hand, phosphorylation and trafficking are completely prevented by mutations of NMBD (but not TMBS) copper-binding sites, demonstrating copper dependence of both PKD-assisted phosphorylation and trafficking. Furthermore, ATP7B trafficking is markedly reduced by Ser478/Ser481/Ser1121/Ser1453 to alanine mutations. It is therefore clear that PKD plays a key role in copper-dependent serine phosphorylation, permitting high levels of ATP7B protein expression and trafficking. PKD interaction with ATP7B is evidently dependent on the presence of the NMBD and its occupancy by copper.
Figure 5
Intracellular distribution of ATP7B in COS-1 cells expressing WT ATP7B (A) or ATP7B subjected to mutations at Asp1027 (B), at Ser478, Ser481, Ser1121 and Ser1453 (C), at the transmembrane domain (TMBS) copper site (D) or at the sixth NMBD copper site (E)
Note the presence of cytosolic trafficking vesicles of WT ATP7B and even following Asp1027 mutation, but no trafficking following serine, NMBD or TMBS copper site mutations. All panels present different fields of cells treated identically. A copper load (200 μM) was added to the culture medium 2 h following infection with adenovirus vector for delivery of ATP7B cDNA (WT or mutant). The cells were fixed 24 h later. Secondary antibodies were goat anti-mouse conjugated with Alexa Fluor® 488 for the ATP7B c-Myc tag (green) and donkey anti-rabbit conjugated with Cy5 (indodicarbocyanine) for Golgi (blue). Red indicates nuclei stained with propidium iodide. Scale bar, 10 μm. This Figure was adapted from J. Biol. Chem. [60] Pilankatta, R., Lewis, D. and Inesi G. Involvement of protein kinase D in expression and trafficking of ATP7B (copper ATPase). Journal of Biological Chemistry. 2011; 286, 7389–7396.
Intracellular distribution of ATP7B in COS-1 cells expressing WT ATP7B (A) or ATP7B subjected to mutations at Asp1027 (B), at Ser478, Ser481, Ser1121 and Ser1453 (C), at the transmembrane domain (TMBS) copper site (D) or at the sixth NMBD copper site (E)
Note the presence of cytosolic trafficking vesicles of WT ATP7B and even following Asp1027 mutation, but no trafficking following serine, NMBD or TMBS copper site mutations. All panels present different fields of cells treated identically. A copper load (200 μM) was added to the culture medium 2 h following infection with adenovirus vector for delivery of ATP7B cDNA (WT or mutant). The cells were fixed 24 h later. Secondary antibodies were goat anti-mouse conjugated with Alexa Fluor® 488 for the ATP7Bc-Myc tag (green) and donkey anti-rabbit conjugated with Cy5 (indodicarbocyanine) for Golgi (blue). Red indicates nuclei stained with propidium iodide. Scale bar, 10 μm. This Figure was adapted from J. Biol. Chem. [60] Pilankatta, R., Lewis, D. and Inesi G. Involvement of protein kinase D in expression and trafficking of ATP7B (copperATPase). Journal of Biological Chemistry. 2011; 286, 7389–7396.It should be understood that the PKD-assisted phosphorylation of serine residues is implicated in cellular trafficking of mammaliancopper ATPases, but is not required for the occurrence of the ATPase catalytic cycle itself. In fact, the catalytic cycle of bacterial copper ATPases occurs without any observable phosphorylation of serine residues.It is of interest that ATP7A, even though sustaining identical catalytic kinetics as ATP7B, has a lower level of serine phosphorylation, and a significant level of glycosylation which is not observed at all with ATP7B [61]. It is then apparent that a specific feature of ATP7A is glycosylation which, in conjunction with subtle changes of amino acid sequence [45], determines stabilization on plasma membranes (Figure 6), and may explain its functions in copper homoeostasis.
Figure 6
Association of ATP7A protein with the plasma membrane of COS-1 cells
Cisplatin is a platinum-containing anticancer drug whose effectiveness is reduced following repeated administrations. Development of resistance is attributed to various mechanisms, including unfavourable drug accumulation and efflux by ATP7A and ATP7B, whose expression is often increased in parallel with cisplatin resistance [62-67]. Cisplatin is accumulated in membrane vesicles obtained from Sf9 cells expressing ATP7B, indicating active transport of the drug by the ATP7BATPase [68]. On the other hand, expression of an ATP7B segment (NMBD) including four copper-binding motifs protects bacterial cells from toxic effects of cisplatin, suggesting that cisplatin binding to the ATPaseNMBD is involved and may be sufficient to produce drug resistance [69,70].Recent electrical measurements performed with membrane fractions of COS-1 cells expressing ATP7A (or ATP7B), and adsorbed on to a solid supported membrane (see above for technical details), demonstrate the occurrence of charge transfer (Figure 7) upon addition of ATP in the presence of micromolar concentrations of cisplatin or oxaliplatin [71], in analogy with measurements performed in the presence of copper [58]. Furthermore, mutations within the NMBD segment, or of the Asp1044 residue involved in formation of phosphoenzyme intermediate, interfere with cisplatin-related charge transfer as well as with copper charge transfer. These experiments indicate that a charged cisplatin complex (presumably bearing the amine groups [71]) undergo ATP-dependent vectorial displacement by ATP7A and ATP7B with a mechanism analogous to that of copper, requiring occupancy of the NMBD sites for catalytic activation of the ATPase [58,72]. The cisplatin complex would then undergo transfer into cytosolic vesicles or across plasma membranes, which is likely to be a factor in the mechanism of cisplatin resistance in anticancer therapy.
Figure 7
Current signals developed by ATP7A on a solid supported membrane in the presence of cisplatin or oxaliplatin
As described above, although PII-type ATPases sustain active transport of alkali and alkali-earth free ions (i.e. Na+, Ca2+) against electrochemical gradients across defined membranes, PIB-type ATPases undergo trafficking from/to various membrane compartments, transferring transition metal ions (i.e. Cu+) from delivery to acceptor proteins. In conformity with other P-ATPases, the free energy of ATP is utilized by copper ATPases through formation of a phosphoenzyme intermediate, yielding protein conformational changes that affect orientation and affinity of cation-binding sites. A specific feature of copper ATPases is the NMBD, which is required for catalytic regulation, and interaction with other proteins. Phosphorylation of serine residues and glycosylation are involved in interactions and trafficking of mammaliancopper ATPases. Cisplatin, a platinum-containing anticancer agent, interacts with mammalianATPase with a mechanism analogous to copper.
Authors: Roohangiz Safaei; Preston L Adams; Mohammad H Maktabi; Ryan A Mathews; Stephen B Howell Journal: J Inorg Biochem Date: 2012-03-03 Impact factor: 4.155
Authors: Francesco Tadini-Buoninsegni; Gianluca Bartolommei; Maria Rosa Moncelli; Rajendra Pilankatta; David Lewis; Giuseppe Inesi Journal: FEBS Lett Date: 2010-10-21 Impact factor: 4.124
Authors: Sivaram Chintalapati; Rana Al Kurdi; Anke C Terwisscha van Scheltinga; Werner Kühlbrandt Journal: J Mol Biol Date: 2008-02-12 Impact factor: 5.469
Authors: Brian J Vaccaro; W Andrew Lancaster; Michael P Thorgersen; Grant M Zane; Adam D Younkin; Alexey E Kazakov; Kelly M Wetmore; Adam Deutschbauer; Adam P Arkin; Pavel S Novichkov; Judy D Wall; Michael W W Adams Journal: Appl Environ Microbiol Date: 2016-09-16 Impact factor: 4.792
Authors: Danny Ramos; David Mar; Michael Ishida; Rebecca Vargas; Michaella Gaite; Aaron Montgomery; Maria C Linder Journal: PLoS One Date: 2016-03-02 Impact factor: 3.240